Medical/Pharmaceuticals
111 to Announce Second Quarter 2021 Unaudited Financial Results on August 27, 2021 -Conference Call to Follow
SHANGHAI, Aug. 9, 2021 /PRNewswire/ – 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results f...
2021-08-09 19:30
37160
Life Sciences' Contribution to the US Digital Therapeutics Market to Grow the Fastest amongst all End Users
The US digital therapeutics market is estimated to witness more than three-and-a-half-fold growth reaching$4.54 billion by 2025, at a CAGR of 29.8%, finds Frost & Sullivan SANTA CLARA, Calif., Aug. 9, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis finds that digital therapeutics (DTx) i...
2021-08-09 18:02
2218
Thailand's Jan-June Investment Applications Reach USD12 billion, as FDI Quadruple, E&E and Medical Sectors Continue to Expand, BOI says
BANGKOK, Aug. 9, 2021 /PRNewswire/ -- In the first six months of 2021, Thailand's investment applications increased 14% from the year earlier period in terms of the number of projects, and 158% in combined value, led by increasing foreign direct investment (FDI) applications, sustained growth in ...
2021-08-09 15:35
1920
Antengene and MindRank AI Enter into Collaboration to Advance the Development of Difficult-to-Drug Molecular Targets
SHANGHAI and HONG KONG, Aug. 9, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
2021-08-09 08:30
2629
China NMPA Approves Phase II Clinical Trial of ASC40 for the Treatment of Patients with Acne
HANGZHOU and SHAOXING, China, Aug. 9, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Phase II clinical trial application of ASC40 for the treatment of patients with moderate to severe acne. T...
2021-08-09 08:30
2262
Innovent Announces the Establishment of the Scientific Advisory Board
SAN FRANCISCO and SUZHOU, China, Aug. 9, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2021-08-09 08:04
4163
Insightec Announces Seoul National University Hospital Is Installing Exablate Neuro Platform
Expanding patient access to incision-free Focused Ultrasound treatment
HAIFA, Israel and MIAMI, Aug. 9, 2021 /PRNewswire/ -- Insightec
2021-08-09 08:00
995
NUH's Smallest Surviving Baby Discharged Well to Home
SINGAPORE, Aug. 7, 2021 /PRNewswire/ -- Kwek Yu Xuan is a 14-month-old infant who had undergone and survived an incredible life battle when she first came into the world. Born prematurely at 212 grams on9 June 2020, in the midst of the global COVID-19 pandemic, this small and fragile baby had a l...
2021-08-07 15:00
2519
FibroBiologics Announces Inaugural Board of Directors
Company Announces Formation of Board of Directors HOUSTON, Aug. 6, 2021 /PRNewswire/ -- FibroBiologics, a clinical stage company developing fibroblast-based therapeutic solutions for chronic diseases, announced today the formation of its Board of Directors. Leading this group is Chairman,Pete ...
2021-08-06 22:01
2774
Endurance Longevity Announces Positive Profit Alert for Interim Results 2021 and Other Exciting Business Updates
HONG KONG, Aug. 6, 2021 /PRNewswire/ -- Endurance RP Limited's ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) is pleased to announce a positive profit alert for the interim results 2021 for the six month period ended30 June 2021. The ...
2021-08-06 20:02
46995
ImmVira's MVR-T3011 Obtained NMPA's Approval for Intravenous Administration (IV) Phase I Clinical Trial
SHENZHEN, China, Aug. 6, 2021 /PRNewswire/ -- ImmVira announced that as a global first, its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011), obtained approval from National Medical Products Administration (" NMPA") for clinical trial for treatments using intravenous adminis...
2021-08-06 19:50
2375
AI and Big Data Join Hands to Assist Physicians in Diagnosis and Reporting
TAIPEI, Aug. 6, 2021 /PRNewswire/ -- With the advent of the 5G era and the growing popularity of big data and artificial intelligence applications, the Joint Commission ofTaiwan (JCT) is hosting Smart Healthcare Expo Taipei 2021: International Smart Healthcare Forum (Session 2) with a focus on tw...
2021-08-06 17:00
2114
ORI Capital's Portfolio Company Pillar Receives FDA Premarket Approval for its oncoReveal(TM) Dx Lung and Colon Cancer Test
HONG KONG, Aug. 6, 2021 /PRNewswire/ -- ORI Capital, a quantamental healthcare fund manager focused on investing in disruptive healthcare companies globally, announced today the U.S. Food and Drug Administration (FDA) has given its portfolio company, Pillar Biosciences Inc. ("Pillar"), Premarket ...
2021-08-06 12:56
2288
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
HONG KONG, Aug. 5, 2021 /PRNewswire/ -- Akeso, Inc. (9926.HK, the "Company" or "Akeso") announced that the anti PD-1 monoclonal antibody drugPenpulimab monoclonal antibody injection co-developed by the Company with Sino Biopharmaceutical Limited (stock code: 1177.HK), has obtained marketing appr...
2021-08-06 09:39
27904
SURGLASSES' SPINE NAVIGATION SYSTEM CADUCEUS S - An innovation greatly influencing minimally invasive surgeries
TAICHUNG, Aug. 6, 2021 /PRNewswire/ -- Taiwan Main Orthopaedic Biotechnology Co. Ltd (SURGLASSES),Taiwan, a company striving to bring a difference into the real time surgical procedure after the introduction of the first AR assisted Head Mounted Display Foresee-X, is now coming up with a new prod...
2021-08-06 08:00
3846
Updated Overall Survival Data and Biomarker Results from Sintilimab ORIENT-11 Study in First-Line Nonsquamous Non-Small Cell Lung Cancer Published in the Journal of Thoracic Oncology
SAN FRANCISCO and SUZHOU, China, Aug. 6, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major dis...
2021-08-06 08:00
22536
Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination
* Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series * Six-fold increase in cross-reactive functional antibodies to Delta variant compared to primary vaccination series * Analysis of sera from primary ...
2021-08-06 05:03
8010
Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine
- Novavax and Serum Institute of India file regulatory submissions to the Drugs Controller General ofIndia and to regulatory agencies in Indonesia and Philippines for Novavax' recombinant nanoparticle COVID-19 vaccine - Filing for World Health Organization Emergency Use Listing expected in Augus...
2021-08-06 04:41
7331
Advanced Instruments to Acquire Solentim, a Trusted Global Leader in Cell Imaging for Cell Line Development and Clone Characterization
NORWOOD, Mass., Aug. 6, 2021 /PRNewswire/ -- Advanced Instruments, a leading manufacturer of analytical instruments and services for bioprocessing, today announced the execution of a definitive agreement to acquire Solentim, a trusted global leader of solutions for the isolation and characterizat...
2021-08-06 02:00
2845
Brii Biosciences Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19
846 outpatients at high risk of clinical progression have been enrolled in the ACTIV-2 phase 2/3 clinical study, from sites inthe United States, Brazil, South Africa, Mexico and Argentina. The participants are being evaluated for the combined endpoint of hospitalizations and death relative ...
2021-08-05 22:46
4110
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 292 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 290 media titles]
2024-04-22 06:00
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 287 media titles]
2024-04-18 21:26
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 286 media titles]
2024-04-19 13:25
Animated Life in Yunnan
[Picked up by 281 media titles]
2024-04-18 14:00
Most Read
Combining Sustainability and Cybersecurity: Century Iron & Steel and Century Wind Power Both Receive ISO 27001 Information Security Certification
2024-04-19 18:03
9063
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
2024-04-18 21:26
8837
Animated Life in Yunnan
2024-04-18 14:00
7825
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
2024-04-19 13:25
7743
IQAX eBL Wins Prestigious APTFF Trade Facilitation Innovation Award 2024
2024-04-18 10:36
3907